Sales Support
U.S.: 
+1-206-701-6702
+1-206-701-6702U.K.: 
+44-020-8133-4027
+44-020-8133-4027JAPAN: 
+050-5539-1737
+050-5539-1737INDIA: 
+91-848-285-0837
+91-848-285-0837 +1-206-701-6702 +44-020-8133-4027 +050-5539-1737 +91-848-285-0837
Cervical dysplasia is typically associated with human papillomavirus (HPV) infection, smoking, and is more common in women above age 30. However, cervical dysplasia is a preventable and cervical screening tests are useful to diagnosis precancerous stage.
Statistics:
The global cervical dysplasia market is estimated to account for US$ 447.7 Mn in terms of value by the end of 2019.
Global Cervical Dysplasia Market: Drivers
Increasing investment in cervical dysplasia is expected to propel growth of the global cervical dysplasia market over the forecast period. For instance, in June 2020, Cel-Sci, a phase 3 cancer immunotherapy company, raised approximately US$ 10 million through the exercise of warrants.
Global Cervical Dysplasia Market: Opportunities
Leveraging virtual space is expected to offer lucrative growth opportunities for players in the global cervical dysplasia market. Diagnosing cervical dysplasia in first world countries such as the U.S. has minimized the death rate of cervical cancer. However, logistics behind this diagnosis process is difficult to implement in developing countries due to women from remote villages rarely return to the clinic for follow-ups. Smartphone application is developed to provide a point-of-care preliminary diagnosis. Ultimately, the application would screen samples obtained and immediately provide a preliminary diagnosis
Global Cervical Dysplasia Market: Restraints
Low awareness of cervical dysplasia in emerging economies is expected to hinder growth of the global cervical dysplasia market. Majority of women in emerging economies still do not have a clear understanding about cervical cancer screening tests and its early detection. Additionally, in low-resource settings, effective screening awareness programs have been difficult to implement, thereby increasing the cervical cancer mortality rates.
Key Takeaways:
The global cervical dysplasia market was valued at US$ 447.7 Mn in 2019 and is forecast to reach a value of US$ 784.8 by 2027 at a CAGR of 7.3% between 2020 and 2027. Increasing prevalence of cervical cancer is expected to drive the market growth during the forecast period.
Diagnostic Test segment held dominant position in the global cervical dysplasia market in 2019, accounting for 86.8% share in terms of value, increasing technological advancement along with product approvals is expected to assist the segment growth.
Market Trends
Adoption of AI for predictive cancer is expected to propel growth of the global cervical dysplasia market over the forecast period. For instance, in September 2020, Google Cloud received a contract to supply Veterans Affairs hospitals and Defense Health Agency treatment facilities with AI for predictive cancer and disease diagnosis.
Moreover, development of advanced diagnostic tools is also expected to aid in growth of the global cervical dysplasia market. For instance, in June 2020, researchers from the Institute of Advanced Study in Science and Technology, India, reported development of a robust fully automated software-based solution using Pap smear images to detect abnormal growth or development of tissues in the cervix — the lower part of the uterus that connects to the vagina.
Global Cervical Dysplasia Market: Competitive Landscape
Major players operating in the global cervical dysplasia market include, F. Hoffmann La-Roche Ltd., QIAGEN N.V., Becton, Dickinson and Company, OncoHealth Corporation, Quest Diagnostics, Inc., Hologic, Inc., Abbott Laboratories, ASKA Pharmaceutical Co., Ltd., Asieris Pharmaceuticals, BetterLife Pharma Inc., and KinoPharma, Inc.
Global Cervical Dysplasia Market: Key Developments
Major players in the global cervical dysplasia market are focused on approval and launch of new products to expand their product portfolio. For instance, in July 2020, Asieris Pharmaceuticals, a China-based biotech company, received Clinical Trial Approval (CTA) from China's National Medical Products Administration (NMPA) for the global, multi-centered Phase III clinical trial of its photodynamic drug-device combination product, APL-1702 (Cevira), which is being developed for the non-surgical treatment of high-grade cervical dysplasia.
Segmentation
Scope of the report
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Contact Us
